Related Experiment Videos
Role of calcium antagonists in systemic hypertension
Insights
Calcium antagonists are effective first-line hypertension treatments, unlike traditional vasodilators. They lower blood pressure without causing significant fluid retention, making them suitable for monotherapy.
Area of Science:
- Cardiovascular Pharmacology
- Nephrology
Background:
- Traditional vasodilators (e.g., hydralazine, minoxidil) are often third or fourth-line treatments for hypertension due to side effects like tachycardia and sodium retention.
- These agents cannot be used as sole antihypertensive therapy.
Purpose of the Study:
- To evaluate the suitability of calcium antagonists as first-line monotherapy for hypertension.
- To compare the hemodynamic and fluid balance effects of calcium antagonists with traditional vasodilators.
Main Methods:
- Review of the antihypertensive actions of calcium antagonists (verapamil, dihydropyridines) and traditional vasodilators.
- Analysis of effects on heart rate, renin activity, and sodium/water balance.
Main Results:
- Calcium antagonists effectively lower blood pressure via vasodilation.
- Unlike traditional vasodilators, calcium antagonists do not cause significant tachycardia or sodium retention; some even promote natriuresis.
- Long-term administration of calcium antagonists does not lead to fluid volume expansion.
Conclusions:
- Calcium antagonists are well-suited for hypertension monotherapy due to their favorable hemodynamic and fluid balance profiles.
- Updated treatment guidelines consider calcium antagonists as potential first-choice agents for hypertension management.
Abstract:
Despite the physiologic rationale of their use in hypertension, traditional vasodilators such as hydralazine and minoxidil are often relegated to the second and, more often, to the third and fourth steps of step-care programs. Although they are powerful blood pressure-lowering agents, they cause tachycardia, excessive renin stimulation and sodium retention, and cannot be used as the only antihypertensive agent. The characteristics of the antihypertensive action of calcium antagonists make them suitable for monotherapy. Indeed, all calcium antagonists, while effectively lowering blood pressure through vasodilation, either do not affect heart rate (verapamil and its analogs) or cause a moderate and transient heart rate increase (dihydropyridine compounds). Dihydropyridines also possess a natriuretic effect, probably due to inhibition of tubular sodium transport. The natriuretic effect is evident during the first 2 days of administration, but a small negative sodium balance persists for at least 1 week. There is no increase in body weight or fluid volumes with long-term administration of calcium antagonists with a marked acute natriuretic response, such as dihydropyridines, and those antagonists with a very moderate immediate natriuretic response, such as verapamil. All calcium antagonists, therefore, appear capable of preventing the sodium and water retention that vasodilatation would otherwise entail. More liberal step-care guidelines are now possible to find the agent most suitable for the individual patient. In these guidelines, calcium antagonists, as well as angiotensin converting enzyme inhibitors, are considered as possible first-choice agents along with diuretics and beta blockers.